Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation

2006 ◽  
Vol 120 (5) ◽  
pp. 1036-1045 ◽  
Author(s):  
Annette Vangsted ◽  
Peter Gimsing ◽  
Tobias W. Klausen ◽  
Bjørn A. Nexø ◽  
Håkan Wallin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Treatment Outcome ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Autologous Bone

scholarly journals High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma

Blood ◽  
1987 ◽  
Vol 70 (3) ◽  
pp. 869-872 ◽  
Author(s):  
B Barlogie ◽  
R Alexanian ◽  
KA Dicke ◽  
G Zagars ◽  
G Spitzer ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
High Dose ◽  
Autologous Bone ◽  
Total Body ◽  
High Dose Melphalan

Abstract Seven patients with advanced multiple myeloma, refractory to therapy with alkylating agent-VAD (vincristine-adriamycin-dexamethasone), received a regimen combining high-dose melphalan with total body irradiation supported by autologous bone marrow transplantation. Very rapid, usually greater than 90% tumor mass reduction was achieved in six patients, regardless of prior chemotherapy responsiveness and marrow plasmacytosis up to 30%. Despite signs of early relapse in three patients (median remission duration of all patients, 15 months), five remain alive and well without further cytotoxic therapy from 2 to 21 months (median, 9+ months). Two patients died, one from surgical complications after transplantation and a second due to persistent neutropenia with fatal pneumonia. This treatment provides meaningful disease control for selected patients with resistant myeloma and a poor prognosis.

Sign in / Sign up

Export Citation Format

Share Document